The pitch vs. the reality

Both drugs are neuroactive steroids that boost GABAergic signaling, a pathway thought to be disrupted after childbirth. In clinical trials, participants taking these medicines did show improvements on the 17-item Hamilton Depression Rating Scale (HAM-D-17). But so did participants on placebo—and that matters when we ask, “Is the drug’s added benefit meaningful enough to justify the cost, logistics, and side-effects?”

Take zuranolone. In the pivotal phase 3 SKYLARK study of women with severe PPD, the average improvement in HAM-D at day 15 was about −17.8 points with zuranolone versus −13.6 with placebo—a difference of ~4.2 points. That met statistical significance, but placebo produced a large absolute improvement on its own, and the drug–placebo gap was modest. Whether ~4 points is “clinically meaningful” is debated; many psychometric analyses put the minimal clinically important difference for HAM-D-17 in the ~4–6-point range, which sits right on the cusp of that result. Meanwhile, everyone—on drug and on placebo—continued to improve over time. (PubMed, PMC)

Brexanolone’s phase 3 trials tell a similar story: significant reductions in HAM-D versus placebo at 60 hours and sustained at day 30, but with large placebo improvements and drug–placebo differences that are statistically positive yet practically modest. Again, the scale moves in both arms; the question is whether the incremental benefit is worth what it takes to get it. (PMC)

Side-effects and real-world frictions

These aren’t benign, pop-a-pill SSRIs.

• Brexanolone requires a continuous 60-hour IV infusion in a certified facility under an FDA REMS program because of risks of excessive sedation and sudden loss of consciousness. Continuous monitoring and assistance during interactions with the infant are required. For a new mother, possibly breastfeeding, juggling childcare—this is a major logistical lift. (FDA Access Data)
• Zuranolone is oral and avoids the infusion, but it carries a boxed warning for driving and hazardous activities: patients should not drive for at least 12 hours after each dose due to CNS-depressant effects. It also lists common adverse effects like somnolence, dizziness, diarrhea, and fatigue, and includes warnings for suicidal thoughts/behavior. That’s not trivial in the postpartum period, when parents often must drive themselves and their newborns to appointments. (FDA Access Data, U.S. Food and Drug Administration, Zurzuvaehcp)

The price tag (and what else that money could buy)

Now the costs.

• Brexanolone (Zulresso): approximately $34,000 for a single 60-hour course before facility fees. Some analyses peg the average drug + administration costs even higher (~$38,000). Access is limited and coverage varies. (Medical News Today, Managed Healthcare Executive, PMC)
• Zuranolone (Zurzuvae): wholesale price $15,900 for a 14-day oral course. Again, coverage varies and specialty-pharmacy distribution applies. (Reuters, Managed Healthcare Executive, MGH Women’s Mental Health Center)

For those sums, families or insurers could fund weeks to months of night-nanny/postpartum doula support, targeted psychotherapy, or comprehensive sleep-protective interventions—supports that directly address two of the strongest and most modifiable drivers of postpartum mood symptoms: sleep disruption and overload without hands-on help.

Is there an RCT showing that a night nanny beats zuranolone on HAM-D? No; head-to-head trials don’t exist. But the sleep–PPD link is robust, and behavioral interventions that protect maternal sleep and build practical support have repeatedly improved depressive symptoms in postpartum populations:

• Sleep disturbance is strongly associated with PPD; systematic reviews and population studies consistently show that worse postpartum sleep tracks with higher depressive symptoms. (jognn.org, PMC)
• Targeted sleep education/behavioral programs around birth improve maternal sleep, confidence, and transition to parenting—and in randomized studies have reduced postpartum depressive symptoms, especially in at-risk groups. (PMC, JCSM)
• Doula support (prenatal through postpartum) is linked to better maternal mental health, with emerging program evaluations suggesting benefits across outcomes where continuous, practical support is central. While not HAM-D trials per se, they underscore that more hands-on help often means fewer mood symptoms. (PMC, Policy Center for Maternal Mental Health)

Given that the drug–placebo separation is modest and that placebo-arm participants improved a lot, it’s reasonable to ask whether sleep-protective, support-heavy care (night feed coverage, lactation troubleshooting, structured nap windows, and practical household help) may deliver bigger real-world gains for many families—at a fraction of the price and without CNS-depressant warnings. (PubMed)

What I tell patients

1. Start with proven, accessible basics.
   High-quality psychotherapy (CBT, IPT), aggressive sleep protection, lactation and feeding support matched to maternal goals, and structured practical help. These address what day-to-day life actually looks like for a new mother, often the primary drivers of suffering. (And yes, an insurer could fund a night doula for several weeks for less than a single course of zuranolone.) (jognn.org, PMC)
2. Use standard antidepressants when indicated.
   SSRIs/SNRIs have decades of data, are affordable, and compatible with breastfeeding in many cases. They don’t require inpatient infusions, 12-hour driving restrictions, or specialty distribution. (Comparative cost analyses highlight just how stark the difference is—on the order of tens of dollars for SSRIs versus tens of thousands for brexanolone.) (PMC)
3. Reserve brexanolone/zuranolone for narrow scenarios.
   If a patient has severe, refractory PPD, cannot tolerate or has failed standard options, and can safely navigate the monitoring/logistics, a fast-acting neuroactive steroid might be worth discussing. But we should be transparent: placebo responses are significant, and the incremental benefit is modest relative to cost and burden. (PMC, PubMed)

Bottom line

Do brexanolone and zuranolone “work”? In trials, yes—statistically—but so did placebo, and the drug–placebo difference is small to moderate at best. Meanwhile, side-effects, monitoring, and access hurdles are nontrivial, and the prices are eye-watering: about $34,000 for one 60-hour brexanolone infusion and $15,900 for a 14-day zuranolone course. For that kind of money, investing in sleep-focused, hands-on postpartum support (night nanny/doula), evidence-based therapy, and standard antidepressants will, for many families, deliver more relief with far less risk. (FDA Access Data, Medical News Today, Managed Healthcare Executive)

If you’re weighing these medications, the honest conversation is not “drug or nothing.” It’s “Which mix of sleep, support, and medicine will move the needle most for you?” For most new parents, the most powerful levers are rest and real help—not a $16,000 pill or a $34,000 infusion.

El Camino Women’s Medical Group offers the latest Minimally Invasive Solutions for gynecologic problems.   Drs. Amy Teng, Erika Balassiano, Pooja Gupta,  and Vivian Wan, all members of AAGL (American Association of Gynecologic Laparoscopy), are highly trained and experienced in the field of Minimally Invasive Gynecologic Surgery.   Dr. Erika Balassiano has also completed a Minimally Invasive Gynecologic Surgery Fellowship under the supervision of world-renowned Dr. Camran Nezhat.   Angel Wong, PA-C, is a physician assistant who sees patients for routine and lower-acuity care.

All of our physicians are El Camino Hospital doctors and operate and deliver at the Mountain View campus.

As part of El Camino Women’s Medical Group’s commitment to comprehensive care for women, we offer in-network mental health services with world-renowned psychiatrist Dr. Rania Awaad and experienced therapist Daniya Ahmed, LMFT.  For women seeking to improve their health through a healthier diet, Mariam AlAgha, MS, is an excellent nutritionist with over a decade of success helping women achieve their health goals.   Her services are also in network.

Serving Mountain View, Los Altos, Los Altos Hills, Atherton, Palo Alto, Redwood City, Burlingame, Saratoga, Cupertino, Sunnyvale, Los Gatos, Campbell, San Jose, Santa Clara, Silicon Valley, Milpitas, Fremont, South Bay, East Bay, and North Bay.